Other intangible assets—net
Bristol-Myers Squibb Other intangible assets—net decreased by 4.5% to $18.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.9%, from $22.49B to $18.24B. Over 5 years (FY 2020 to FY 2025), Other intangible assets—net shows a downward trend with a -18.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase often signals successful R&D capitalization or strategic acquisitions of intellectual property, while a decrease may indicate amortization or impairment.
Detailed definition
This represents the net book value of identifiable non-physical assets such as patents, trademarks, and acquired drug li...
Peer comparison
High for research-intensive pharmaceutical companies compared to service-based industries.
non_current_assets_intangible_assets_net_excluding_goodwillHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.07B | $44.93B | $42.53B | $40.1B | $37.69B | $38.18B | $35.86B | $33.57B | $31.3B | $28.95B | $27.07B | $32.76B | $29.43B | $26.96B | $23.31B | $22.49B | $21.38B | $20.47B | $19.1B | $18.24B |
| QoQ Change | — | -6.5% | -5.3% | -5.7% | -6.0% | +1.3% | -6.1% | -6.4% | -6.8% | -7.5% | -6.5% | +21.0% | -10.2% | -8.4% | -13.6% | -3.5% | -4.9% | -4.3% | -6.7% | -4.5% |
| YoY Change | — | — | — | — | -21.6% | -15.0% | -15.7% | -16.3% | -16.9% | -24.2% | -24.5% | -2.4% | -6.0% | -6.9% | -13.9% | -31.4% | -27.4% | -24.1% | -18.0% | -18.9% |
Other intangible assets—net at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's other intangible assets—net?
- Bristol-Myers Squibb (BMY) reported other intangible assets—net of $18.24B in Q1 2026.
- How has Bristol-Myers Squibb's other intangible assets—net changed year-over-year?
- Bristol-Myers Squibb's other intangible assets—net decreased by 18.9% year-over-year, from $22.49B to $18.24B.
- What is the long-term trend for Bristol-Myers Squibb's other intangible assets—net?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's other intangible assets—net has grown at a -18.5% compound annual growth rate (CAGR), from $53.24B to $19.1B.
- What does other intangible assets—net mean?
- The value of non-physical assets like patents and licenses, excluding goodwill.